- Home
- SNTG vs GLTO Comparison
SNTG vs GLTO Comparison
Compare SNTG & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- GLTO
- Stock Information
- Founded
- SNTG 2009
- GLTO 2011
- Country
- SNTG China
- GLTO Denmark
- Employees
- SNTG N/A
- GLTO N/A
- Industry
- SNTG Finance: Consumer Services
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- SNTG Finance
- GLTO Health Care
- Exchange
- SNTG Nasdaq
- GLTO Nasdaq
- Market Cap
- SNTG 4.8M
- GLTO 4.0M
- IPO Year
- SNTG 2021
- GLTO 2020
- Fundamental
- Price
- SNTG $1.85
- GLTO $3.29
- Analyst Decision
- SNTG
- GLTO Buy
- Analyst Count
- SNTG 0
- GLTO 1
- Target Price
- SNTG N/A
- GLTO $10.00
- AVG Volume (30 Days)
- SNTG 22.7K
- GLTO 86.7K
- Earning Date
- SNTG 06-17-2025
- GLTO 05-08-2025
- Dividend Yield
- SNTG N/A
- GLTO N/A
- EPS Growth
- SNTG N/A
- GLTO N/A
- EPS
- SNTG N/A
- GLTO N/A
- Revenue
- SNTG $107,507.00
- GLTO N/A
- Revenue This Year
- SNTG N/A
- GLTO N/A
- Revenue Next Year
- SNTG N/A
- GLTO N/A
- P/E Ratio
- SNTG N/A
- GLTO N/A
- Revenue Growth
- SNTG N/A
- GLTO N/A
- 52 Week Low
- SNTG $1.43
- GLTO $2.01
- 52 Week High
- SNTG $3.97
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- SNTG 54.50
- GLTO 59.33
- Support Level
- SNTG $1.66
- GLTO $3.05
- Resistance Level
- SNTG $1.75
- GLTO $3.49
- Average True Range (ATR)
- SNTG 0.07
- GLTO 0.26
- MACD
- SNTG -0.00
- GLTO 0.04
- Stochastic Oscillator
- SNTG 68.75
- GLTO 75.76
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.